FDA’s Promising New Framework for Rare Genetic Diseases

This JAMA Forum discusses the opportunities and challenges facing US Food and Drug Administration (FDA) new approval paths for individualized therapies to treat rare genetic diseases.

Corresponding Author: Scott Gottlieb, MD, American Enterprise Institute, 1150 17th St NW, Washington, DC 20036 (scott.gottlieb@gmail.com).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.